What research findings does CBL-514 have regarding the reduction of local subcutaneous fat?
CBL-514 improves doctor/patient ratings and MRI-measured fat volume. Another study reports: reduction in abdominal subcutaneous fat volume; about 69.6% achieved ≥150 mL reduction in 8 weeks.[1] ↗ [2] ↗
Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
Comparison of study design and results
Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.
| Literature | Study subjects and design | Observation and discovery | Scope of Explanation |
|---|---|---|---|
| 2026 · PMID 42159040 | Human random stage IIb; Local abdominal fat | CBL-514 improves doctor/patient ratings and MRI-measured fat volume. | Clinically developed formulation, cannot be equated with research materials on the website. |
| 2025 · PMID 40037659 | Human single-blind placebo-controlled randomized Phase II | Decrease in abdominal subcutaneous fat volume; Approximately 69.6% decrease to ≥150 mL after 8 weeks. | Short-term local body shaping endpoints, not full-body weight loss. |
| 2022 · PMID 35709509 | Human dose-exploration Phase IIa | Specific dosage reduced abdominal fat volume and thickness. | 2022 early study; dosing density and full bottle specifications cannot be mixed up. |
References
What are the changes in MRI and scoring in phase IIb local fat study?
CBL-514 improves doctor/patient ratings and MRI-measured fat volume.[1] ↗
Human random stage IIb; Local abdominal fat
Clinically developed formulation, cannot be equated with research materials on the website.
View the Article Title and Full Citation＋
Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-reported Outcomes and MRI Assessment.
Aesthetic Surgery Journal · Volume and Year 2026
First published 2026-05-20 · PMID 42159040
DOI 10.1093/asj/sjag092
What has been observed in the Abdominal Subcutaneous Fat Randomized Trial?
Decrease in abdominal subcutaneous fat volume; Approximately 69.6% decrease to ≥150 mL after 8 weeks.[2] ↗
Human single-blind placebo-controlled randomized Phase II
Short-term local body shaping endpoints, not full-body weight loss.
View the Article Title and Full Citation＋
Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study.
Aesthetic Surgery Journal · Volume and Year 2025
First published 2025-05-01 · PMID 40037659
DOI 10.1093/asj/sjaf032
What were the findings of early local fat trials of CBL-514?
Specific dosage reduced abdominal fat volume and thickness.[3] ↗
Human dose-exploration Phase IIa
2022 early study; dosing density and full bottle specifications cannot be mixed up.
View the Article Title and Full Citation＋
Efficacy of a Novel Injection Lipolysis to Induce Targeted Adipocyte Apoptosis: A Randomized, Phase IIa Study of CBL-514 Injection on Abdominal Subcutaneous Fat Reduction.
Aesthetic Surgery Journal · Volume and Year 2022
First published 2022-10-01 · PMID 35709509
DOI 10.1093/asj/sjac162
Common issues and corresponding evidence
What research findings does CBL-514 have regarding the reduction of local subcutaneous fat?＋
CBL-514 improves doctor/patient ratings and MRI-measured fat volume. Another study reports: reduction in abdominal subcutaneous fat volume; about 69.6% achieved ≥150 mL reduction in 8 weeks.[1] ↗ [2] ↗
CBL-514
Return to catalog specifications and batch file verification entry.
